• Hizentra is the first, ready-to-use, 20% liquid preparation of human IgG specifically formulated for SCIG, which:
-effectively protects PI patients from serious and nonserious bacterial infections; -labeled for secondary immunodeficiencies outside the US; -has a good safety profile; -is easily stored for up to 30 months at up to 25ºC, whilst retaining predefined values; -is easily infused using conventional pumps; is well tolerated in children; -is well tolerated in children; -has generally mild-to-moderate local AEs. • Fewer related systemic AEs.
Ease of administration gives patients a sense of independence and responsibility.
• Administration performed at a location convenient for the patient avoiding convenient for the patient, avoiding unnecessary travel and potential nosocomial infections.
• SCIG administered into the extravascular SCIG administered into the extravascular compartment (see figure) , resulting in more sustained serum IgG levels, avoiding the peaks and troughs associated with IVIG.
Hizentra efficacy advantages
• Hizentra achieved clinical efficacy in patients with PI with stable and physiologically relevant serum IgG levels and no serious bacterial infections.
• Clinical trials with Hizentra resulted in mean trough levels found in healthy individuals, and was also well tolerated in children.
HRQL markedly improved upon switching from IVIG to Hizentra; with a significant improvement observed in the "convenience" domain.
• SCIG typically administered once a week due • SCIG typically administered once a week due to high infusion rates (Hizentra infusion rates between 25.3-35.0 mL/hr).
• 20% concentration benefits children as the required dose can be delivered in a small volume.
Jolles S, Sleasman JW. Advances in Therapy. 2011; 28:521-533. 20% concentration benefits children as the required dose can be delivered in a small volume.
• Hizentra has a high purity (≥98% IgG; trace amounts of IgA) and no preservatives. g p y ( g ; g ) p
• Screened for hepatitis B and C, HIV, and B19 virus.
• Overall prion reduction and viral reduction, ranging from >10 7 to >10 24 , depending on viral model.
• Stabilized with a nonessential natural amino acid L-Proline (250 mmol/L) Stabilized with a nonessential, natural amino acid, L Proline (250 mmol/L).
• Hizentra storage at 25ºC for up to 30 months shows values within predefined specifications (content of aggregates, monomers/dimers, Fc function).
• Simplifies product storage at pharmacies and for patients at home.
Safety benefits of Hizentra administration
• Hizentra indicated for treatment of PIs, including congenital agammaglobulinemia, CVID, XLA, and Wiskott-Aldrich syndrome.
• Labeled for secondary immunodeficiencies outside the US.
• Good safety profile, effectively protecting PI patients from serious and nonserious bacterial infections.
• In clinical trials, systemic AEs such as headache, fatigue, and nausea were relatively rare, whilst no serious AEs were considered to be related to Hizentra.
• Local AEs were generally mild to moderate and transient decreasing in frequency over • Local AEs were generally mild-to-moderate and transient, decreasing in frequency over time.
SCIG administration advantages
• No need for hospital visits; can be administered at a location convenient for the patient.
• Self-administration with Hizentra was shown to be easy to learn.
• Supervision of initial administrations by a nurse or healthcare professional, followed by a home visit.
• Infusion can be administered using a conventional pump or a "Push technique": between one and seven injections a week using a syringe and a 23-25-gauge butterfly needle.
• Training sessions detail needle gauge and length, selection of infusion sites, aseptic infusion, and management of AEs. , g
• Requires no pump or tubing and is time and cost effective; hence, an attractive option to patients and insurance companies.
SCIG conventional pumps
• Hizentra preparations can also be administered with conventional pumps.
• FREEDOM60 Syringe Infusion system (top); most widely used in the US: simple, reliable, and not dependent p , , p on batteries or electrical outlets.
• Multiple Crono pumps are available and used, such as the Crono Super-PID (bottom) and Cane Crono PCA-50 pump. Crono Super PID (bottom) and Cane Crono PCA 50 pump.
• The Crono Super-PID is standard for patients commencing SCIG in Cardiff, UK, and are specified with home care packages provided home care packages provided.
Summary
• SCIG administrations improve on IVIG infusions by: p y -having more stable serum IgG levels -avoidance of peaks and troughs; -allowing administration in patients with poor venous access; -giving patients the option to administer SCIG themselves -more convenient.
• Benefits of 20% Hizentra include:
-efficacious against serious and nonserious bacterial infections; d d d ti f d i i t ti -reduced duration of administration; -good safety profile, including administration in children; -easily stored and administered using traditional pumps; -easy to learn following initial training; easy to learn following initial training; -generally mild-to-moderate local AEs; -most local reactions are mild and decrease in frequency over time.
